CEO of Mammogen highlights the benefits of blood-based cancer detection
9 October 2026
Rockford News First | October 9, 2026
Rockford News First featured Mammogen CEO Elizabeth Cormier-May in a news segment discussing the growing role of blood-based testing in cancer detection.
During the interview, Cormier-May explains how Mammogen is using RNA-powered technology to support earlier breast cancer detection, particularly for women with dense breast tissue. She also discusses how blood-based diagnostics could complement traditional mammography and help make cancer screening more accessible.
Mammogen announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors as an Independent Director. Dr. Epstein brings decades of experience in genomics, precision medicine, and oncology diagnostics, including leadership roles with Illumina, Veracyte, and Decipher Biosciences. His appointment strengthens Mammogen's leadership as the company continues advancing genTRU-breast™, its RNA-powered blood-based assay designed to support earlier breast cancer detection, through clinical validation and toward commercialization. Click Here to Read the Full Press Release →
Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen
YouTube | Video Interview Mammogen founder Marty Keiser discusses the evolving diagnostics industry and the challenges facing companies that depend on insurance reimbursement and traditional payer models. The conversation explores the changing healthcare landscape and what these shifts could mean for diagnostics companies as they work to bring innovative technologies to market. Click Here to Watch the Full Interview →
NBC 10 News featured Mammogen CEO Elizabeth Cormier-May in its coverage of the evolving landscape of blood-based cancer detection and an upcoming FDA advisory committee review of GRAIL’s Galleri test. Cormier-May shared her perspective on the significance of liquid biopsy technology and discussed how Mammogen’s approach differs by focusing specifically on earlier breast cancer detection. The story also highlights Mammogen’s blood-based test and its potential role in supporting women who may need additional testing following their annual mammogram. Read the full article on NBC 10 News →